A novel cell immunoassay to measure survival of motor neurons protein in blood cells

[1]  Susanna M. Grzeschik,et al.  Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells , 2005, Annals of neurology.

[2]  Xiaocun Chen,et al.  Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. , 2005, Human molecular genetics.

[3]  J. Yong,et al.  The Survival of Motor Neurons Protein Determines the Capacity for snRNP Assembly: Biochemical Deficiency in Spinal Muscular Atrophy , 2005, Molecular and Cellular Biology.

[4]  C. Lorson,et al.  A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. , 2005, Human molecular genetics.

[5]  M. Baiget,et al.  Implication of Fetal SMN2 Expression in Type I SMA Pathogenesis: Protection or Pathological Gain of Function? , 2005, Journal of neuropathology and experimental neurology.

[6]  E. Bertini,et al.  Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients , 2005, European Journal of Human Genetics.

[7]  B. Stockwell,et al.  Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. , 2004, Chemistry & biology.

[8]  T. Crawford.  Concerns about the design of clinical trials for spinal muscular atrophy , 2004, Neuromuscular Disorders.

[9]  Jeongsik Yong,et al.  Why do cells need an assembly machine for RNA-protein complexes? , 2004, Trends in cell biology.

[10]  E. Bertini,et al.  Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy , 2004, European Journal of Human Genetics.

[11]  K. Fischbeck,et al.  Valproic acid increases SMN levels in spinal muscular atrophy patient cells , 2003, Annals of neurology.

[12]  Y. Hofmann,et al.  Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. , 2003, Human molecular genetics.

[13]  E. Androphy,et al.  Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. , 2001, Human molecular genetics.

[14]  Y. Jong,et al.  Treatment of spinal muscular atrophy by sodium butyrate , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Yong,et al.  The Y14 protein communicates to the cytoplasm the position of exon–exon junctions , 2001, The EMBO journal.

[16]  T. Gilliam,et al.  Differential SMN2 expression associated with SMA severity , 1998, Nature Genetics.

[17]  G. Dreyfuss,et al.  The Spinal Muscular Atrophy Disease Gene Product, SMN, and Its Associated Protein SIP1 Are in a Complex with Spliceosomal snRNP Proteins , 1997, Cell.

[18]  T. Crawford,et al.  The survival motor neuron protein in spinal muscular atrophy. , 1997, Human molecular genetics.

[19]  Arnold Munnich,et al.  Correlation between severity and SMN protein level in spinal muscular atrophy , 1997, Nature Genetics.

[20]  T. Crawford,et al.  The Neurobiology of Childhood Spinal Muscular Atrophy , 1996, Neurobiology of Disease.

[21]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.

[22]  J. Pearn.  CLASSIFICATION OF SPINAL MUSCULAR ATROPHIES , 1980, The Lancet.

[23]  H. Prytz,et al.  Letter: Kupffer cells and cirrhosis. , 1975, Lancet.